sorry, we can't preview this file
12885_2019_5704_MOESM5_ESM.tif (1.18 MB)
Additional file 5: of Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
figure
posted on 2019-05-23, 05:00 authored by Huan Deng, Yu Huang, Zhengdong Hong, Xuhui Yuan, Zhi Cao, Yiping Wei, Wenxiong ZhangFigure S4. Beggâs and Eggerâs tests for comparisons of ORR (A) and DCR (B) associated with pazopanib versus sunitinib. (TIF 1210 kb)